In the 90-day study trial, 180 adults with mild knee OA received either placebo, Maxicuma® 100 mg or 250 mg once daily. Outcomes were assessed using WOMAC (symptom severity), VAS (pain intensity), and a treadmill walk test (functional performance/mobility) at 30, 45, 60, and 90-day intervals.
After 12 weeks of supplementation, both Maxicuma® doses produced significant improvement compared to placebo (p ≤ 0.0001).
- Pain scores reduced by 70% compared to baseline
- WOMAC function scores reduced nearly by 80% compared to baseline
- Physical function improved by more than 90% from baseline
“Joint health is one of the most popular nutraceutical categories, and while curcumin is well known for its anti-inflammatory potential, its poor bioavailability has historically limited clinical efficacy,” said Arumugam Raghavan, Head of Sales and Marketing at Ennature Biopharma.
“This clinical trial demonstrates that Maxicuma® (clean label certified) effectively overcomes this barrier—delivering clinical benefits at lower doses (100–250 mg).”
Maxicuma®, with its clinically validated efficacy at a lower dose, offers an ideal solution for formulators and brands developing joint and mobility supplements for active adults, athletes, and the healthy aging population.
To explore formulation opportunities or access the full study, visit: www.maxicuma.com or email ennature@indiaglycols.com
Refrences:
1. Efficacy and safety investigation of LIMAN technology based curcumin formulation on knee osteoarthritis: a randomised double-blind placebo-controlled trial. European Journal of Integrative Medicine, Volume 79, October 2025, 10253. https://doi.org/10.1016/j.eujim.2025.102531
2. Anti-osteoarthritic Effect of High Bioavailable Curcumin Formulation by Balancing Cartilage Synthesis and Cartilage Degradation in MIA-induced Osteoarthritis Rats. https://doi.org/10.1177/09731296251326792
